Savvy investors often eye the biotech sector for growth stocks with the potential for enormous gains. Artificial intelligence (AI) has significantly boosted the odds of medical breakthroughs in gene therapy, cancer, rare disease therapeutics, and RNA-based medications. Clinical-stage biotech companies, in particular, have one or more drugs in clinical trials, which, when successful, has the potential to cause the company’s stock to skyrocket.
One such company is Kura Oncology (KURA), which has transitioned recently from a clinical-stage to a commercial-stage biotech company now that the U.S. Food and Drug Administration (FDA) has approved one of its cancer drugs. While the stock is down 24% year-to-date (YTD), Wall Street believes Kura stock has the potential to surge as high as 850% in 2026.
